Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Famitinib Malate Capsules in Healthy Subjects
NCT05336279Phase 1Completed
- Sponsor
- Hengrui
- Start
- May 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of famitinib in solid tumor (2 arms), sponsored by Hengrui. Primary endpoints: Maximum observed plasma concentration of Famitinib, Area under the plasma concentration versus time curve (AUC0-t) of Famitinib and 1 more. Started May 2022; status: completed.
02
Drugs
famitinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05336279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05336279.